Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106534 · ClinicalTrials.gov registry record · Phase 4
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
A Phase 4 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 870
- Enrollment target
NCT01106534: Completed Phase 4 study, sponsored by Abbott Medical Devices.
NCT01106534 is a Phase 4 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 870 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106534, a Phase 4 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 870 participants
- Enrollment target
Study Summary
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.
Interventions
- DRUG placebo + aspirin
- DRUG clopidogrel + aspirin OR prasugrel + aspirin
- DEVICE XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-07 |
| Phase | Phase 4 |
What the finished NCT01106534 record still lists
NCT01106534 is an interventional study that assigns participants to a tested intervention. The registered 870 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo + aspirin is the first listed.
NCT01106534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01106534 about?
NCT01106534 is a clinical study titled "XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort". XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet ther...
What is the current status of trial NCT01106534?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 870 participants. The study started on 2009-08. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01106534?
The interventions under investigation include: placebo + aspirin (DRUG), clopidogrel + aspirin OR prasugrel + aspirin (DRUG), XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) (DEVICE).
Who is sponsoring clinical trial NCT01106534?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01106534's enrollment target sits among peer trials
870 87th of 2000 higher than 1,913 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia